New York, January 14, 2026, 14:54 EST — During regular session
- Shares of Praxis Precision Medicines climbed roughly 8% by mid-afternoon.
- The company appointed epilepsy expert Dr. Orrin Devinsky to lead its clinical strategy.
- Two FDA drug applications are scheduled for mid-February, drawing traders’ focus.
Shares of Praxis Precision Medicines jumped roughly 8% on Wednesday, bucking the weaker trend in the broader market. By mid-afternoon, the Nasdaq-listed biotech was trading at $303.23, up $22.40.
The move came after Praxis announced late Tuesday it hired epilepsy expert Dr. Orrin Devinsky for a new head of clinical strategy role. Steven Petrou, president of research and development, said Devinsky’s choice to join “reflects the strength of our scientific approach and long-term strategy.” GlobeNewswire
Timing is crucial since investors zero in on regulatory filings that can shift a biotech’s valuation overnight. A New Drug Application, or NDA, is what drugmakers send to the U.S. Food and Drug Administration to get approval to market a drug. The FDA’s Breakthrough Therapy designation aims to fast-track development and review when early data hints a drug might outperform existing treatments.
Biotech led gains, with the SPDR S&P Biotech ETF climbing roughly 1.8%, while the iShares Nasdaq Biotechnology ETF added about 0.5%. Meanwhile, the Nasdaq-focused QQQ and the S&P 500 tracker SPY fell more than 0.8% each.
Praxis highlighted Devinsky’s decades-long focus on epilepsy research and his role as a principal investigator in trials that secured the first FDA approval for cannabidiol therapy targeting several rare epilepsies. “Praxis represents a rare convergence of scientific rigor, translational ambition, and genuine commitment to patients,” Devinsky commented. Finviz
The company is focusing on therapies for central nervous system disorders caused by neuronal signaling imbalances. Its pipeline includes programs built on both a small-molecule platform and an antisense oligonucleotide platform. The firm currently has four late-stage candidates targeting movement disorders and epilepsy.
Praxis revealed its 2026 plan earlier this week, aiming for two NDA submissions by mid-February: ulixacaltamide for essential tremor, a disorder causing severe shaking, and relutrigine targeting SCN2A/8A developmental and epileptic encephalopathies, a rare genetic epilepsy. The company also pointed to multiple registrational readouts scheduled for 2026 and reported having $1.5 billion in pro forma cash and investments. CEO Marcio Souza noted the company’s focus now “broadens from clinical execution to commercial readiness.” GlobeNewswire
Praxis just closed an underwritten public offering, selling 2.212 million shares at $260 each, aiming to raise roughly $575 million before fees. While this move reduces funding pressure, it also dilutes existing shareholders—a factor investors usually factor into the stock price right away.
But the risk remains. The FDA warns that Breakthrough Therapy designation doesn’t ensure approval. Delays in review or requests for additional data can extend timelines and slam high-multiple biotech stocks.
Investors are focused on the company’s anticipated NDA submissions in mid-February, along with any insights into the FDA review timeline. The next major catalyst probably won’t emerge until trial results start coming in 2026, which could swing either direction.
